异动解读｜BioNTech SE盘中上涨23.13%，mRNA癌症疫苗三期试验成功提振板块

行情直击08-19

8月19日，BioNTech SE盘中上涨23.13%，报114.09美元/股，成交额4.27亿美元。

消息面上，Moderna与默沙东联合研发的mRNA黑色素瘤癌症疫苗三期临床试验取得成功，被市场视为mRNA技术平台在肿瘤治疗领域的历史性突破。BioNTech作为全球领先的mRNA技术平台公司，该试验成功直接验证了其核心技术路线在癌症免疫治疗中的广阔前景，带动公司股价大幅走高。当日生物科技板块全线上涨，Moderna涨超127%，诺瓦瓦克斯医药涨超6%。

BioNTech SE成立于2008年，专注于结合免疫学与mRNA等尖端治疗平台，开发针对癌症和其他疾病的个体化免疫疗法。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1194520061?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-19 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194520061","market":"hk","top_or_hot":-1,"title":"异动解读｜BioNTech SE盘中上涨23.13%，mRNA癌症疫苗三期试验成功提振板块","media":"行情直击","content":"<p><p>8月19日，BioNTech SE盘中上涨23.13%，报114.09美元/股，成交额4.27亿美元。</p><p>消息面上，Moderna与默沙东联合研发的mRNA黑色素瘤癌症疫苗三期临床试验取得成功，被市场视为mRNA技术平台在肿瘤治疗领域的历史性突破。BioNTech作为全球领先的mRNA技术平台公司，该试验成功直接验证了其核心技术路线在癌症免疫治疗中的广阔前景，带动公司股价大幅走高。当日生物科技板块全线上涨，Moderna涨超127%，诺瓦瓦克斯医药涨超6%。</p><p>BioNTech SE成立于2008年，专注于结合免疫学与mRNA等尖端治疗平台，开发针对癌症和其他疾病的个体化免疫疗法。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜BioNTech SE盘中上涨23.13%，mRNA癌症疫苗三期试验成功提振板块</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜BioNTech SE盘中上涨23.13%，mRNA癌症疫苗三期试验成功提振板块\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-19 22:16 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月19日，BioNTech SE盘中上涨23.13%，报114.09美元/股，成交额4.27亿美元。消息面上，Moderna与默沙东联合研发的mRNA黑色素瘤癌症疫苗三期临床试验取得成功，被市场视为mRNA技术平台在肿瘤治疗领域的历史性突破。BioNTech作为全球领先的mRNA技术平台公司，该试验成功直接验证了其核心技术路线在癌症免疫治疗中的广阔前景，带动公司股价大幅走高。当日生物科技板块全线...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"","article_id":"1194520061","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194520061","pubTimestamp":1787149018,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"8月19日，BioNTech SE盘中上涨23.13%，报114.09美元/股，成交额4.27亿美元。消息面上，Moderna与默沙东联合研发的mRNA黑色素瘤癌症疫苗三期临床试验取得成功，被市场视为mRNA技术平台在肿瘤治疗领域的历史性突破。BioNTech作为全球领先的mRNA技术平台公司，该试验成功直接验证了其核心技术路线在癌症免疫治疗中的广阔前景，带动公司股价大幅走高。BioNTech SE成立于2008年，专注于结合免疫学与mRNA等尖端治疗平台，开发针对癌症和其他疾病的个体化免疫疗法。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"Movement Interpretation | BioNTech SE rose 23.13% in the intraday session, and the successful phase III trial of mRNA cancer vaccine boosted the sector","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"8月19日，BioNTech SE盘中上涨23.13%，报114.09美元/股，成交额4.27亿美元。消息面上，Moderna与默沙东联合研发的mRNA黑色素瘤癌症疫苗三期临床试验取得成功，被市场视为mRNA技术平台在肿瘤治疗领域的历史性突破。BioNTech作为全球领先的mRNA技术平台公司，该试验成功直接验证了其核心技术路线在癌症免疫治疗中的广阔前景，带动公司股价大幅走高。当日生物科技板块全线上涨，Moderna涨超127%，诺瓦瓦克斯医药涨超6%。BioNTech SE成立于2008年，专注于结合免疫学与mRNA等尖端治疗平台，开发针对癌症和其他疾病的个体化免疫疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194520061","isCrawlerRequest":true}